SCHEMBL19680034

SCHEMBL19680034

O=C(O)c1ccccc1Nc1cc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)c2noc3c2c1C(=O)c1ccccc1-3

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAUR Q03405 3/20 0.70
PLAU P00749 1/20 0.52
NTRK1 P04629 1/20 0.51
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
POLB P06746 3/20 0.50
APAF1 O14727 2/20 0.50
USP2 O75604 2/20 0.50
EHMT2 Q96KQ7 7/20 0.49
MAPT P10636 2/20 0.49
THRB P10828 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
APP P05067 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
SNCA P37840 1/20 0.49
BRCA1 P38398 1/20 0.49
GSK3B P49841 2/20 0.49
NSD2 O96028 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15939902 0.80 KMT2A (0.76) MEN1KMT2APOLBAPAF1USP2
SCHEMBL19687291 0.77 NR1H4 (0.47) PLAURKMT2AUSP2TSHRNR1H4
SCHEMBL12698666 0.76 PLAUR (1.00) PLAURPLAUNTRK1MEN1KMT2A
SCHEMBL2483448 0.73 EHMT2 (0.61) PLAURPLAUNTRK1MEN1KMT2A
SCHEMBL2628847 0.73 NTRK1 (0.74) PLAURPLAUNTRK1POLBEHMT2
SCHEMBL13285004 0.72 NTRK1 (0.62) PLAURPLAUNTRK1MEN1KMT2A
SCHEMBL17874500 0.70 PLAU (0.81) PLAURPLAUNTRK1EHMT2MAPT
SCHEMBL15940016 0.69 MEN1 (0.74) PLAURMEN1KMT2APOLBAPAF1
SCHEMBL12499325 0.69 PLAU (1.00) PLAURPLAUNTRK1EHMT2MAPT
SCHEMBL30019219 0.69 PLAU (1.00) PLAURPLAUNTRK1EHMT2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170348266-A1 INHIBITION OF PROLINE CATABOLISM FOR THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS BUCK INSTITUTE FOR RESEARCH ON AGING 2017-12-07 US disclosed
US-20170348266-A1 INHIBITION OF PROLINE CATABOLISM FOR THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS BUCK INSTITUTE FOR RESEARCH ON AGING 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348266-A1 INHIBITION OF PROLINE CATABOLISM FOR THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS GLUL, GLS2, PHGDH PLAUR 2892/4885PLAU 2041/4885NTRK1 3780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.